USFDA approved Lupin to sell Pioglitazone tablets in America

Apr 11, 2014 17:45 IST

US Food and Drug Administration (USFDA) on 10 April 2014 approved Lupin to sell generic diabetes management drug Pioglitazone tablets in the American market. USFDA’s approval has been granted for the tablets in strengths of 15 mg, 30 mg and 45 mg. The company will shortly commence marketing the product in US.


Pioglitazone is indicated as second or third line treatment of type 2 diabetes as monotherapy and dual oral therapy.  It is also indicated for combination with insulin in type 2 diabetes mellitus in adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.

About Lupin
• Lupin Pharmaceuticals, Inc. is the US wholly owned subsidiary of Lupin Limited in India.
• The Company delivers the high-quality, branded and generic medications across the world.
• The company has a state-of-the-art R&D center in Pune which is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and cardiovascular drugs. It has a notable presence in the areas of diabetes, anti-inflammatory and respiratory therapy.

Quick Digest

Who: Lupin Limited

Where: America

What: sell Pioglitazone tablets

When: 10 April 2014

Is this article important for exams ? Yes28 People Agreed
Read more Current Affairs on: USFDA , Pioglitazone , Lupin Limited

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK